Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CYTH Stock Forecast 2025-2026
$0.00
Current Price
$0
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CYTH Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
CYTH Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
0.0%
1 Year Change
0.0%
Year-to-Date Change
nan%
From 52W High of $0.00
nan%
From 52W Low of $0.00
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Cyclo Therapeutics (CYTH) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CYTH and similar high-potential opportunities.
Latest CYTH Stock Price Targets & Analyst Predictions
Comprehensive analyst forecasts are currently unavailable for CYTH. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CYTH Analyst Ratings
0
Buy
0
Hold
0
Sell
CYTH Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.00
Latest CYTH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CYTH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
(CYTH) Competitors
The following stocks are similar to Cyclo Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
(CYTH) Financial Data
has a market capitalization of $0 with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of N/A.
Valuation Metrics
Market Cap
$0
Enterprise Value
$0
P/E Ratio
0.0x
PEG Ratio
0.0x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
nan%
Current Ratio
0.0x
Debt/Equity
0.0x
ROE
N/A
ROA
N/A
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
(CYTH) Business Model
(CYTH) Latest News & Analysis
Latest News
Quick Summary
KSF is investigating the proposed merger between Cyclo Therapeutics, Inc. (CYTH) and Rafael Holdings, Inc. (RFL) for potential fairness to shareholders.
Why It Matters
Concerns over the fairness of Cyclo Therapeutics' merger with Rafael Holdings could impact share prices and investor confidence, potentially affecting trading strategies.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cyclo Therapeutics (Nasdaq: CYTH) announced data presentation from its Phase 3 study on Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 at the 21st Annual WOR.
Why It Matters
The presentation of Phase 3 data for Trappsol® Cyclo™ signals potential advancements in treatment for Niemann-Pick Disease, possibly impacting Cyclo Therapeutics' stock value and future growth.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) will present abstracts at the 21st Annual WORLDSymposium™ from February 3-7, 2025, in San Diego, highlighting its advancements in biomedicine.
Why It Matters
Cyclo Therapeutics' acceptance to present at a major symposium highlights its advancements in biotechnology, potentially boosting investor confidence and interest in the company's future prospects.
Source: Business Wire
Market Sentiment:
Neutral
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders
4 months ago
Quick Summary
Halper Sadeh LLC is investigating Liberty TripAdvisor Holdings, Inc. and Cyclo Therapeutics, Inc. for potential securities law violations related to their sales and mergers. Shareholders may have legal options.
Why It Matters
Concerns over potential legal violations in mergers may affect share prices and investor sentiment for Liberty TripAdvisor and Cyclo Therapeutics, influencing trading decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
ResearchAndMarkets.com has added a report on Niemann-Pick disease, detailing over 10 companies and 12 pipeline drugs, including profiles and assessments of therapeutic products.
Why It Matters
The report on Niemann-Pick disease pipeline offers insights into potential investment opportunities in biotechnology, highlighting active and inactive products that could impact market dynamics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cyclo Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
6 months ago
Quick Summary
Cyclo Therapeutics (Nasdaq: CYTH) reported its Q3 2024 financial results, highlighting significant clinical and corporate advancements. Further details on business developments were provided.
Why It Matters
Cyclo Therapeutics' advancements and financial results could signal growth potential, impacting stock performance and investor confidence in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About CYTH Stock
What is 's (CYTH) stock forecast for 2025?
Analyst forecasts for (CYTH) are not currently available. The stock is trading at $0.00.
Is CYTH stock a good investment in 2025?
Analyst ratings for CYTH are not currently available. The stock is currently trading at $0.00. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CYTH stock?
Price predictions from Wall Street analysts for CYTH are not currently available. The stock is trading at $0.00.
What is 's business model?
N/A
What is the highest forecasted price for CYTH ?
Price targets from Wall Street analysts for CYTH are not currently available. The stock is trading at $0.00.
What is the lowest forecasted price for CYTH ?
Price targets from Wall Street analysts for CYTH are not currently available. The stock is trading at $0.00.
What is the overall CYTH consensus from analysts for ?
Analyst ratings for CYTH are not currently available. The stock is trading at $0.00.
How accurate are CYTH stock price projections?
Stock price projections, including those for , are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 16, 2025 3:04 AM UTC